<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02682745</url>
  </required_header>
  <id_info>
    <org_study_id>HL-BPSR-101</org_study_id>
    <nct_id>NCT02682745</nct_id>
  </id_info>
  <brief_title>Single Dosing Clinical Trial of HL151</brief_title>
  <official_title>Single Dosing Clinical Trial to Assess the Pharmacokinetic Characteristics and Safety/Tolerability of HL151 Formulation in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hanlim Pharm. Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hanlim Pharm. Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the pharmacokinetic characteristics of bepotastine&#xD;
      after single oral administration of TALION tab, a IR formulation of bepotastine as reference&#xD;
      drug and HL151, a SR formulation of bepotastine as test drug in healthy male adults.&#xD;
      Additionally the safety and tolerability of two drugs will be evaluated.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 15, 2016</start_date>
  <completion_date type="Actual">February 12, 2016</completion_date>
  <primary_completion_date type="Actual">February 12, 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the plasma concentration versus time curve (AUC)</measure>
    <time_frame>24 hours after single administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Peak Plasma Concentration (Cmax)</measure>
    <time_frame>24 hours after single administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>Participants will be followed for the duration of study medication dosing days and hospital stay, and follow-up period for maximum 5 days from the discharge</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Rhinitis, Allergic, Perennial</condition>
  <arm_group>
    <arm_group_label>R-T1-T2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>First period: administration of reference drug, Second period: administration of test drug l, Third period : administration of test drug ll</description>
  </arm_group>
  <arm_group>
    <arm_group_label>R-T2-T1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>First period : administration of reference drug, Second period : administration of test drug ll, Third period : administration of test drug l</description>
  </arm_group>
  <arm_group>
    <arm_group_label>T1-T2-R</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>First period : administration of test drug l, Second period : administration of test drug ll, Third period : administration of reference drug</description>
  </arm_group>
  <arm_group>
    <arm_group_label>T1-R-T2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>First period : administration of test drug l, Second period : administration of reference drug, Third period : administration of test drug ll</description>
  </arm_group>
  <arm_group>
    <arm_group_label>T2-R-T1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>First period : administration of test drug ll, Second period : administration of reference drug, Third period : administration of test drug l</description>
  </arm_group>
  <arm_group>
    <arm_group_label>T2-T1-R</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>First period : administration of test drug ll, Second period : administration of test drug l, Third period : administration of reference drug</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HL151</intervention_name>
    <description>Test drug l : HL151, 1T, single oral administration on an empty stomach, Test drug ll : HL151, 1T, single oral administration after meal</description>
    <arm_group_label>R-T1-T2</arm_group_label>
    <arm_group_label>R-T2-T1</arm_group_label>
    <arm_group_label>T1-R-T2</arm_group_label>
    <arm_group_label>T1-T2-R</arm_group_label>
    <arm_group_label>T2-R-T1</arm_group_label>
    <arm_group_label>T2-T1-R</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TALION tab.</intervention_name>
    <description>Reference drug: TALION tab, 1T, every 12 hours, oral administration</description>
    <arm_group_label>R-T1-T2</arm_group_label>
    <arm_group_label>R-T2-T1</arm_group_label>
    <arm_group_label>T1-R-T2</arm_group_label>
    <arm_group_label>T1-T2-R</arm_group_label>
    <arm_group_label>T2-R-T1</arm_group_label>
    <arm_group_label>T2-T1-R</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy male volunteer in the age of 19-45&#xD;
&#xD;
          2. Body weight≥50kg and BMI 18~29 kg/m2&#xD;
&#xD;
          3. Subject who sign on an informed consent form willingly&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subject with serious active cardiovascular, respiratory, hepatologic, renal,&#xD;
             hematologic, gastrointestinal, immunologic, dermal, neurologic, or psychological&#xD;
             disease or history of such disease&#xD;
&#xD;
          2. Subject with acute disease within 28 days prior to study medication dosing&#xD;
&#xD;
          3. Subject with known for history of disease which affect on the absorption,&#xD;
             distribution, metabolism, excretion of drug&#xD;
&#xD;
          4. Subject with clinically significant chronic disease&#xD;
&#xD;
          5. Positive on the test of HBs Ag, anti-HCV Ab, anti-HIV Ab, VDRL&#xD;
&#xD;
          6. Use of any prescription medication within 14 days prior to study medication dosing&#xD;
&#xD;
          7. Use of any medication such as over-the-counter medication including oriental&#xD;
             medication within 7 days prior to study medication dosing&#xD;
&#xD;
          8. Subject with clinically significant allergic disease&#xD;
&#xD;
          9. Subject with known for hypersensitivity reaction to bepotastine&#xD;
&#xD;
         10. Subject with any of the following conditions in laboratory test&#xD;
&#xD;
               -  AST/ALT &gt; UNL (upper normal limit) x 2&#xD;
&#xD;
               -  Total bilirubin &gt; UNL x 2&#xD;
&#xD;
               -  Renal failure with CLcr &lt; 50mL/min calculated on Cockcroft-Gault [Cockcroft-Gault&#xD;
                  GFR = (140-age) * (Wt in kg) / (72 *Cr)]&#xD;
&#xD;
               -  SBP&lt;100mmHg or ≥160mmHg, DBP&lt;60mmHg or ≥100mmHg&#xD;
&#xD;
               -  QTc&gt;440msec on ECG&#xD;
&#xD;
               -  Serum potassium &lt; 3.5 mEq/L or &gt; 5.5 mEq/L&#xD;
&#xD;
         11. Immunological incompetence, immune deficiency or taking immunosuppressants&#xD;
&#xD;
         12. Subject who cannot take standard meal&#xD;
&#xD;
         13. Subject with whole blood donation within 60days, component blood donation within&#xD;
             20days prior to study medication dosing&#xD;
&#xD;
         14. Subject with blood transfusion within 30days prior to study medication dosing&#xD;
&#xD;
         15. Participation in any clinical investigation within 90days prior to study medication&#xD;
             dosing&#xD;
&#xD;
         16. Continued excessive use of caffeine (caffeine &gt;five cups/day),&#xD;
             alcohol(alcohol&gt;30g/day) and severe heavy smoker(cigarette &gt;10 cigarettes per day)&#xD;
&#xD;
         17. Subject with decision of nonparticipation through investigator's review due to&#xD;
             laboratory test results or other excuse such as non-responding to request or&#xD;
             instruction by investigator&#xD;
&#xD;
         18. Subject taking inducer or inhibitor of drug metabolism enzyme such as barbital within&#xD;
             30days prior to study medication dosing&#xD;
&#xD;
         19. Subject who are not using adequate means of contraception&#xD;
&#xD;
         20. Subject with genetic problems such as galactose intolerance, Lapp Lactase Deficiency&#xD;
             or glucose-galactose malabsorption&#xD;
&#xD;
         21. Subject with history of drug abuse or drug addiction&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>The Korea Univertisy Anam Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>136-705</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>February 3, 2016</study_first_submitted>
  <study_first_submitted_qc>February 12, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 15, 2016</study_first_posted>
  <last_update_submitted>August 16, 2018</last_update_submitted>
  <last_update_submitted_qc>August 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Rhinitis, Allergic</mesh_term>
    <mesh_term>Rhinitis, Allergic, Perennial</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

